New Strategies to Improve Outcomes in Patients with Epilepsy
This CME Program will provide clinicians with a comprehensive review and analysis from the American Epilepsy Society (AES) 2015 Annual Meeting held in Philadelphia, Pennsylvania. Expert faculty will communicate important information for clinical decision-making, as it relates to diagnostic classifications of epilepsy. Recent clinical trial data available and emerging treatment options will also be discussed. This activity will bring clinicians and other health care professionals responsible for the management of patients with epilepsy up to date in order to optimize patient outcomes.
This activity has been designed to meet the educational needs of neurologists, epileptologists, and other healthcare professionals responsible for the treatment of patients with epilepsy.
Upon completion of this activity, participants will be better able to:
- Understand the diagnostic classifications of epilepsy, including the clinical characteristics of seizures presented at AES 2015.
- Interpret clinical trial data pertaining to available and emerging anti-epileptic therapies presented at AES 2015.
- Review the newer data from clinical trials for adjunctive therapy options for patients with primary generalized tonic-clonic seizures.
Michael R. Sperling, MD
Dennis J. Dlugos, MD
Dennis D. Marsh, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Michael R. Sperling, MD
Grant/Research Support: Acorda Therapeutics, Inc., Brain Sentinel, Defense Advanced Research Projects Agency, Eisai Co., Ltd., GlaxoSmithKline, Marinus Pharmaceuticals, Inc., Medtronic, Inc., National Institutes of Health, Pfizer Inc., SK Life Science Inc.,Sunovion Pharmaceuticals Inc., UCB, Inc., Upsher-Smith Laboratories, Inc.,
Dennis J. Dlugos, MD
Has no relationships to disclose
Eric D. Marsh, MD
Consultant/Advisor: GW Pharmaceuticals, Stanley Brothers Social Enterprises
Grant/Research Support: GW Pharmaceuticals
Non-faculty: Sandy Breslow, Alison Kemp, Bernard Abrams, MD, Timothy Hayes, MD, PhD, Kristen Scollon, Emma Gilmartin, Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the last 12 months.
This CME activity has been supported by an independent educational grant from Eisai Co., Ltd.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Eisai Co., Ltd. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician